Juniper Investment Company, LLC sold $2.6M of OFIX (indirect holdings)

Juniper Investment Company, LLC sold 242,000 indirectly-held shares of Orthofix Medical Inc. (OFIX) at $10.70 ($2.59M total) on 2026-05-22.

Original reporting
SEC EDGAR · Juniper Investment Company, LLC
Published May 29, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OFIX
Neutral
medium confidence
Mentioned
$OFIX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXNeutralLow
01

Why it matters

Provides a fresh, dated datapoint on ownership reduction at a specific execution price, which can influence sentiment but does not introduce new operational or regulatory information.

02

Market read

Traders may adjust short-term positioning around OFIX based on incremental supply/sentiment from the disclosed sale.

03

What to watch

Check for clustering of insider sales, changes in total insider ownership, and whether the sale coincides with broader market moves in orthopedics/medical devices.

Relevance 7/10Novelty 7/10Timing: After-hours/next-session positioning based on the latest SEC Form 4 disclosure (filed 2026-05-29).

Background

The article is an SEC Form 4 insider transaction: Juniper Investment Company, LLC (10% owner) sold Orthofix Medical shares on 2026-05-22; the filing was made 2026-05-29.

Company-level read

Ticker impact

$OFIXNeutralMedium confidence
Context

Orthofix Medical’s 10% owner Juniper Investment Company sold 242,000 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Low-to-moderate short-term downside bias; likely limited impact unless accompanied by unusual volume or follow-on filings.

Evidence & confidence

The filing provides a concrete sale size and price ($10.6992) but no accompanying new company-specific operating or guidance information.

Market effects

Minimal—this is a single-company ownership transaction without sector-wide news.

None.

None.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing (no 10b5-1 plan stated), so it may not reflect deteriorating fundamentals.

Key entities

  • Orthofix Medical Inc.

    Subject company whose shares were sold by a 10% owner via open-market sale.

  • Juniper Investment Company, LLC

    10% owner reporting the sale of 242,000 OFIX shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OFIXHighAI 8/10

Orthofix Earnings Call Shows Growth Amid Spine Challenges

Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

Med

Orthofix Medical Inc. Q3 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q3 2026 earnings below expectations due to U.S. Spine market softness and supplier delays. The company is consolidating distributors, with core partners generating 80% of U.S. spinal implant revenue. Updated full-year 2026 revenue guidance is $825M-$830M. Management expects a $22M net sales headwind in 2027 due to European MDR requirements. The VIRATA spinal implant system is set for full market launch in late Q4 2026.

$OFIXMedAI 8/10

Orthofix Medical (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical (OFIX) reported Q3 2026 net sales of $207.9M, up 2.3% YoY. Spine sales fell 1%, while Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively. The company is focusing on strategic partnerships, simplifying its product portfolio, and aligning costs. It expects near-term sales pressure due to these transitions and updated guidance accordingly. Cash reserves stood at $86.9M.

$OFIXMed

Orthofix 3Q 2026: Revenue $207.86M, EPS ($0.15) — 10-Q Summary

Orthofix reported 3Q 2026 revenue of $207.86M, up 1.1% YoY, with a net loss of $6.07M, improved from $22.8M last year. Therapeutic Solutions and Global Limb Reconstruction sales grew, while Spinal Implants and other segments declined. Gross margin fell to 70.5% due to product mix changes. SG&A expenses decreased by $22.8M, driven by lower legal costs and commissions.

$OFIXMed

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Orthofix Medical Inc. (OFIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarte